Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.

Spoiler alert: Three years into separate six-year deals with Bayer and Merck, demand for the contraceptives is even higher than originally forecast. From 4.7 million in 2012, the annual run rate ...

In the past six months, while AbbVie rose the most (3.3%), Merck declined the most (24.8%). Watch this space for regular pipeline and regulatory updates next week. AstraZeneca, AbbVie, Bayer ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

L.L. has acted as a consultant for Merck, Novartis, and Bayer, and has received grants from Pfizer, Bayer, Merck, and Novartis. D.C.B. has served on the steering committee as a consultant for Merck.